Trametinib dimethyl sulfoxide is under clinical development by Novartis and currently in Phase II for Nongerminomatous (Nonseminomatous) Germ Cell Tumors. According to GlobalData, Phase II drugs for Nongerminomatous (Nonseminomatous) Germ Cell Tumors does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Trametinib dimethyl sulfoxide LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Trametinib dimethyl sulfoxide overview
Trametinib (GSK1120212, Mekinist) is an anti-cancer agent. It is formulated as tablets, film coated tablets, coated tablets, powder for solution for oral route of administration. Trametinib is indicated as a single agent or in combination with dabrafenib for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by a FDA-approved test. The use in combination is based on the demonstration of durable response rate. Improvement in disease-related symptoms or overall survival has not been demonstrated for Mekinist in combination with dabrafenib. Mekinist in combination with dabrafenib, for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by a FDA-approved test.
Trametinib is under development for the treatment of cholangiocarcinoma, metastatic biliary tract carcinoma, differentiated thyroid cancer (DTC), gallbladder cancer, lung adenocarcinoma, cetuximab-refractory colorectal cancer in combination with panitumumab, metastatic pancreatic cancer, plexiform neurofibroma, Langerhans cell histocytosis, arterio-venous malformations, anaplastic thyroid cancer, ampulla of Vater cancer). refractory and relapsed Multiple Myeloma, triple-negative breast cancer, endometrial cancer in combination with uprosertibm. It is under development for low grade glioma. It is also underdevelopment for the treatment of solid tumors, which may include but are not limited to rhabdomyosarcoma and other soft tissue sarcomas, Ewing sarcoma family of tumors, osteosarcoma, neuroblastoma, Wilms' tumor, hepatic tumors, germ cell tumors, primary brain tumors, NF-1 associated PF and LCH.
It was under development for the treatment of lymphoma and metastatic uveal melanoma, relapsed or refractory leukemia including acute myeloblastic leukemia, myelodysplastic syndrome, advanced or metastatic biliary tract cancer (cholangiocarcinoma, gallbladder cancer, chronic myelomonocytic leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, chronic myelogenous leukemia ,glioma and metastatic transitional (urothelial) tract cancer and Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation, and it was also under development for the treatment of colorectal cancer, bladder cancer, pancreatic cancer, non-small cell lung cancer, ovarian cancer, head and neck cancer squamous cell carcinoma in combination with uprosertib. Afuresertib in combination with trametinib was under development for the treatment of prostate cancer, renal cell carcinoma, gastric cancer and hepatocellular cancer.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of Trametinib dimethyl sulfoxide’s drug-specific PTSR and LoA scores, buy the report here.